Ruiling Xu

Dr. Ruiling Xu

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Critical Reviews in Microbiology
Verified
Journal Article
Open access
RXRuiling Xu
Ruiling Xu
YZYuxuan Zhang
Yuxuan Zhang
SCShurui Chen
Shurui Chen
YZYaohui Zeng
Yaohui Zeng
XFXuan Fu
Xuan Fu
XZXiaojie Zhang
Xiaojie Zhang
The role of Akkermansia muciniphila, one of the most abundant microorganisms of the intestinal microbiota, has been studied extensively in metabolic diseases, such as obesity and diabetes. It is considered a next-generation probiotic microorganism. Although its mechanism of action has not been fully elucidated, accumulating evidence indicates the important role of A. muciniphila in brain functions via the gut-brain axis and its potential as a therapeutic target in various neuropsychiatric disorders. However, only a limited number of studies, particularly clinical studies, have directly assessed the therapeutic effects of A. muciniphila interventions in these disorders. This is the first review to discuss the comprehensive mechanism of A. muciniphila in the gut-brain axis via the protection of the intestinal mucosal barrier and modulation of the immune system and metabolites, such as short-chain fatty acids, amino acids, and amino acid derivatives. Additionally, the role of A. muciniphila and its therapeutic potential in various neuropsychiatric disorders, including Alzheimer’s disease and cognitive deficit, amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, have been discussed. The review suggests the potential role of A. muciniphila in healthy brain functions.

13 October 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
XWXin-Hong Wang
Xin-Hong Wang
MLMing-Na Liu
Ming-Na Liu
XSXun Sun
Xun Sun
CXChun-Huan Xu
Chun-Huan Xu
JLJing Liu
Jing Liu
BLBao-Xin Li
Bao-Xin Li

18 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RXRuiling Xu
Ruiling Xu
Lin QiLin Qi
Lin Qi
XRXiaolei Ren
Xiaolei Ren
WZWenchao Zhang
Wenchao Zhang
CLChenbei Li
Chenbei Li
ZLZhihong Li
Zhihong Li
Soft tissue sarcoma (STS) is one of the rarest but most aggressive cancer. It is important to note that intratumoral hypoxia and tumor microenvironment (TME) infiltration play a significant role in the growth and therapeutic resistance of STS. The goal of this study was therefore to determine whether linking hypoxia-related parameters to TME cells could provide a more accurate prediction of prognosis and therapeutic response. An analysis of 109 hypoxia-related genes and 64 TME cells was conducted in STS. Hypoxia-TME classifier was constructed based on 6 hypoxia prognostic genes and 8 TME cells. As a result, we evaluated the prognosis, tumor, and immune characteristics, as well as the effectiveness of therapies in Hypoxia-TME-defined subgroups. The Lowplus group showed a better prognosis and therapeutic response than any other subgroup. It is possible to unravel these differences based on immune-related molecules and somatic mutations in tumors. Further validation of Hypoxia-TME was done in an additional cohort of 225 STS patients. Additionally, we identified five key genes through differential analysis and RT-qPCR, namely, ACSM5, WNT7B, CA9, MMP13, and RAC3, which could be targeted for therapy. As a whole, the Hypoxia-TME classifier demonstrated a pretreatment predictive value for prognosis and therapeutic outcome, providing new approaches to therapy strategizing for patients.